The beneficial effect of TRPA1 inhibition on neuroglial cell activation and demyelination has also been shown by a recent computational study, which, by molecular docking techniques, potential TRPA1 selective inhibitors, including desvenlafaxine, paliperidone, and febuxostat (which possess a suitable blood–brain barrier (BBB) permeability) have been reported as the most promising repurposable agents for treating MS [200]. This evidence concerns the gene TRPA1 and myeloid sarcoma.